Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) EBT Margin (2020 - 2025)

Historic EBT Margin for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 0.83%.

  • Xeris Biopharma Holdings' EBT Margin rose 359600.0% to 0.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.88%, marking a year-over-year increase of 291500.0%. This contributed to the annual value of 28.12% for FY2024, which is 106200.0% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its EBT Margin stood at 0.83% for Q3 2025, which was up 359600.0% from 2.7% recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' EBT Margin registered a high of 0.83% during Q3 2025, and its lowest value of 308.95% during Q2 2021.
  • Moreover, its 5-year median value for EBT Margin was 45.95% (2024), whereas its average is 88.29%.
  • In the last 5 years, Xeris Biopharma Holdings' EBT Margin plummeted by -650200bps in 2021 and then surged by 2041400bps in 2022.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' EBT Margin stood at 237.02% in 2021, then soared by 83bps to 40.03% in 2022, then grew by 23bps to 30.7% in 2023, then soared by 72bps to 8.51% in 2024, then surged by 110bps to 0.83% in 2025.
  • Its last three reported values are 0.83% in Q3 2025, 2.7% for Q2 2025, and 15.34% during Q1 2025.